Abstract
Recently, many studies have shown a decrease in myocardial damage in patients undergoing coronary artery bypass surgery where the anesthetic agent used was sevoflurane compared with propofol. The basis for this protective effect of the myocardium occurs through the mechanisms of preconditioning and postconditioning of halogenated agents. Both relate to the benefit of prior or subsequent administration of the drug (halogenated anesthetic agent) to the harmful stimulus for myocardial cells. The two mechanisms have similar effector mechanisms. The intraoperative administration of sevoflurane is common in anesthetic practice, but the continuation of the administration in the first postoperative hours is made possible by the AnaConDa ® device (ACD; Sedana Medical AB, Uppsala, Sweden) designed for halogenated sedation of patients admitted to intensive care units (ICU). This device has proven useful to facilitate the treatment of pathological conditions. The object of our review is to determine if there are beneficial effects to extending exposure to halogenated agents in the immediate post-operative period . In the post-operative phase, the pathological myocardium is in a reperfusion process in the coronary microcirculation and expression of certain receptors and chemical mediators can reduce potential injury secondary to reperfusion of previously hibernating and/or stunned tissue
Keywords: Sevoflurane, propofol, kidney, Anaconda, preconditioning.
Current Pharmaceutical Design
Title:Sevoflurane in Intraoperative and Postoperative Cardiac Surgery Patients. Our Experience in Intensive Care Unit with Sevoflurane Sedation
Volume: 19 Issue: 22
Author(s): Jose Luis Guerrero Orriach, M. Ramirez Aliaga, Manuel Galan Ortega, Manuel Rubio Navarro, Isabel Navarro Arce and Jose Cruz Manas
Affiliation:
Keywords: Sevoflurane, propofol, kidney, Anaconda, preconditioning.
Abstract: Recently, many studies have shown a decrease in myocardial damage in patients undergoing coronary artery bypass surgery where the anesthetic agent used was sevoflurane compared with propofol. The basis for this protective effect of the myocardium occurs through the mechanisms of preconditioning and postconditioning of halogenated agents. Both relate to the benefit of prior or subsequent administration of the drug (halogenated anesthetic agent) to the harmful stimulus for myocardial cells. The two mechanisms have similar effector mechanisms. The intraoperative administration of sevoflurane is common in anesthetic practice, but the continuation of the administration in the first postoperative hours is made possible by the AnaConDa ® device (ACD; Sedana Medical AB, Uppsala, Sweden) designed for halogenated sedation of patients admitted to intensive care units (ICU). This device has proven useful to facilitate the treatment of pathological conditions. The object of our review is to determine if there are beneficial effects to extending exposure to halogenated agents in the immediate post-operative period . In the post-operative phase, the pathological myocardium is in a reperfusion process in the coronary microcirculation and expression of certain receptors and chemical mediators can reduce potential injury secondary to reperfusion of previously hibernating and/or stunned tissue
Export Options
About this article
Cite this article as:
Guerrero Orriach Jose Luis, Aliaga M. Ramirez, Galan Ortega Manuel, Rubio Navarro Manuel, Navarro Arce Isabel and Cruz Manas Jose, Sevoflurane in Intraoperative and Postoperative Cardiac Surgery Patients. Our Experience in Intensive Care Unit with Sevoflurane Sedation, Current Pharmaceutical Design 2013; 19 (22) . https://dx.doi.org/10.2174/1381612811319220008
DOI https://dx.doi.org/10.2174/1381612811319220008 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews CETP Inhibitory Activity of Chlorobenzyl Benzamides: QPLD Docking, Pharmacophore Mapping and Synthesis
Letters in Drug Design & Discovery Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?
Current Vascular Pharmacology Antiviral Drug Discovery Targeting to Viral Proteases
Current Pharmaceutical Design Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology Role of Micronutrients on Subclinical Atherosclerosis Micronutrients in Subclinical Atherosclerosis
Current Pharmaceutical Design Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Statins May Prevent Atherosclerotic Disease in OSA Patients without Co-Morbidities?
Current Vascular Pharmacology The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Current Drug Targets The “Sympathetic” Kidney: Multiples Effects of Renal Sympathetic Nerve Ablation
Current Hypertension Reviews Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Cyanotic Congenital Heart Disease The Coronary Arterial Circulation
Current Cardiology Reviews Spontaneous Pneumothorax
Current Respiratory Medicine Reviews Circulating Biomarkers for the Diagnosis and Prognosis of Heart Failure
Current Medicinal Chemistry